
Mast cells are best known for their involvement in the pathogenesis of allergic reactions and inflammation. Due to the wide variety of activation methods and the various mediators that mast cells can synthesize and store, they can regulate all stages of the inflammatory process. There are a large amount of data describing the role of mast cells in the development of autoimmune rheumatoid arthritis, but their role in the development of inflammatory traumatic osteoarthritis remains poorly described. However, non-autoimmune cartilage damage is the main reason for joint replacement surgeries. As important regulators of the inflammatory process, mast cells could be an interesting target for the treatment of osteoarthritis. Herein, we summarize the knowledge about the role of mast cells in the pathogenesis of osteoarthritis and outline various approaches that, to varying degrees, seem promising for the correction of the disease.
Citation: Anastasiia D. Kurenkova, Peter S. Timashev. Mast cells: A dark horse in osteoarthritis treatment[J]. AIMS Allergy and Immunology, 2022, 6(4): 228-247. doi: 10.3934/Allergy.2022017
[1] | Yujia Xiang, Yuqi Jiao, Xin Wang, Ruizhi Yang . Dynamics of a delayed diffusive predator-prey model with Allee effect and nonlocal competition in prey and hunting cooperation in predator. Electronic Research Archive, 2023, 31(4): 2120-2138. doi: 10.3934/era.2023109 |
[2] | Xiaowen Zhang, Wufei Huang, Jiaxin Ma, Ruizhi Yang . Hopf bifurcation analysis in a delayed diffusive predator-prey system with nonlocal competition and schooling behavior. Electronic Research Archive, 2022, 30(7): 2510-2523. doi: 10.3934/era.2022128 |
[3] | Miao Peng, Rui Lin, Zhengdi Zhang, Lei Huang . The dynamics of a delayed predator-prey model with square root functional response and stage structure. Electronic Research Archive, 2024, 32(5): 3275-3298. doi: 10.3934/era.2024150 |
[4] | Fengrong Zhang, Ruining Chen . Spatiotemporal patterns of a delayed diffusive prey-predator model with prey-taxis. Electronic Research Archive, 2024, 32(7): 4723-4740. doi: 10.3934/era.2024215 |
[5] | Mengting Sui, Yanfei Du . Bifurcations, stability switches and chaos in a diffusive predator-prey model with fear response delay. Electronic Research Archive, 2023, 31(9): 5124-5150. doi: 10.3934/era.2023262 |
[6] | Maurıicio F. S. Lima, Jaume Llibre . Hopf bifurcation for a class of predator-prey system with small immigration. Electronic Research Archive, 2024, 32(7): 4604-4613. doi: 10.3934/era.2024209 |
[7] | Chen Wang, Ruizhi Yang . Hopf bifurcation analysis of a pine wilt disease model with both time delay and an alternative food source. Electronic Research Archive, 2025, 33(5): 2815-2839. doi: 10.3934/era.2025124 |
[8] | Ruizhi Yang, Dan Jin . Dynamics in a predator-prey model with memory effect in predator and fear effect in prey. Electronic Research Archive, 2022, 30(4): 1322-1339. doi: 10.3934/era.2022069 |
[9] | Kerioui Nadjah, Abdelouahab Mohammed Salah . Stability and Hopf bifurcation of the coexistence equilibrium for a differential-algebraic biological economic system with predator harvesting. Electronic Research Archive, 2021, 29(1): 1641-1660. doi: 10.3934/era.2020084 |
[10] | Yichao Shao, Hengguo Yu, Chenglei Jin, Jingzhe Fang, Min Zhao . Dynamics analysis of a predator-prey model with Allee effect and harvesting effort. Electronic Research Archive, 2024, 32(10): 5682-5716. doi: 10.3934/era.2024263 |
Mast cells are best known for their involvement in the pathogenesis of allergic reactions and inflammation. Due to the wide variety of activation methods and the various mediators that mast cells can synthesize and store, they can regulate all stages of the inflammatory process. There are a large amount of data describing the role of mast cells in the development of autoimmune rheumatoid arthritis, but their role in the development of inflammatory traumatic osteoarthritis remains poorly described. However, non-autoimmune cartilage damage is the main reason for joint replacement surgeries. As important regulators of the inflammatory process, mast cells could be an interesting target for the treatment of osteoarthritis. Herein, we summarize the knowledge about the role of mast cells in the pathogenesis of osteoarthritis and outline various approaches that, to varying degrees, seem promising for the correction of the disease.
Dendrolimus is a forest pest with large occurrence and wide damage area. Among them, Dendrolimus superans is mainly distributed in Northeast China, Russia Far East, Japan, and so on. Dendrolimus superans are mainly parasitic on coniferous trees such as Larix gmelinii Kuzen and Pinus tabuliformis Carriere. Their larvae eat a large number of needles, resulting in trees being unable to carry out normal photosynthesis, eventually leading to a wide range of trees being destroyed or killed. Dendrolimus superans is extremely harmful to agriculture and forestry. In addition, the outbreak of Dendrolimus superans leads to tree death, reduces vegetation coverage, changes in plant population structure, and damages forest health and ecosystem stability. The life cycle of Dendrolimus superans consists of four stages: Egg, larva, pupa, and adult. In the life cycle of Dendrolimus superans, their development typically encompasses several key stages: Adult, egg, larva, and pupa, with each stage transitioning closely to the next. Specifically, adult insects will actively approach trees as a crucial behavior for seeking suitable environments to lay eggs. After the adults deposit their eggs on pine needles, the eggs will eventually hatch into larvae. During the larval stage, insects crawl on pine needles; this behavior is likely in search of food resources to meet the demands of their rapid growth and development. Subsequently, the larvae enter the pupal stage, during which they undergo a series of complex physiological and morphological changes. Finally, they metamorphose into adults through a process of transformation, thus completing a full life cycle. This process not only showcases the morphological and behavioral characteristics of insects at different life stages but also reflects their important strategies for adapting to the environment and reproducing. Among these stages, the larval stage is the most damaging to forests. The spread mechanism of the Dendrolimus superans is illustrated in Figure 1.
There are three major methods for the prevention and control of Dendrolimus superans: Physical control, chemical control, and biological control. Among them, physical control is mainly aimed at the behavior patterns and characteristics of Dendrolimus superans. However, this method requires a lot of manpower and material resources, which is not suitable for large-scale prevention and control [1]. Although chemical control is effective for large-scale pests, the use of pesticides and other chemical reagents may cause environmental pollution. By comparison, biological control is an environmentally friendly and sustainable pest control technology. The use of natural biological control of pests reduces the use of chemical pesticides, maintains ecological balance, avoids pest resistance, and is harmless to human health. Therefore, it is suitable for long-term pest control. Dendrolimus superans mostly has two major natural enemies: Parasitic natural enemies and predatory natural enemies. Among the parasitic natural enemies, Trichogramma and Exorista civilis play an important role; in terms of predatory natural enemies, it is represented by Common Cuckoo, Cyanopica cyanus, and so on, as illustrated in Figure 2.
When exploring the interaction between Dendrolimus superans and Cyanopica cyanus, we frequently employ the predator-prey model for analysis. This model is crucial for understanding and studying the dynamic changes in the predator-prey relationship between these two species within the realm of mathematical biology. In other studies, scholars have continuously refined and optimized these models [2,3,4,5,6,7]. The flight distance of adult female Dendrolimus superans is about 1.5 km, which shows that there are some limitations in their dispersal ability. Therefore, in the study of predator-prey model, the research environment can be regarded as relatively isolated. In such a relatively closed natural environment, scholars are concerned about the various factors that affect the system. Some biological studies have shown that habitat complexity affects population size and growth trends, indicating the important role of habitat complexity in the construction of ecological communities [8,9,10]. In addition, the construction of mixed forests provides habitat for natural enemies, increases environmental complexity, creates an ecological environment that is not conducive to the growth and development of Dendrolimus superans, and can effectively control the population of Dendrolimus superans [11,12]. Therefore, it is of great significance to study the biological control of Dendrolimus superans and their impact on forest ecosystems by using mathematical models. Based on the Lotka-Volterra model[13], Ma and Wang[14] proposed a predator-prey model with time delay and habitat complexity, that is
{dudt=ru(1−uK)−c(1−β)uαv1+ch(1−β)uα,dvdt=ec(1−β)uα(t−τ)v(t−τ)1+ch(1−β)uα(t−τ)−dv, | (1.1) |
where u and v describe the population of prey and predator, respectively. r is the intrinsic growth rate of prey. K is the capacity of environmental for prey. c is the attack rate of predator. β stands for the strength of habitat complexity. h is the handling time of predator. e is the conversion efficiency. τ is the gestation delay of predator. d is the death rate of predator. α is a positive real number. All parameters in model (1.1) are positive.
The relationship between Dendrolimus superans and its natural enemies is typically characterized using the predator-prey model. The functional response, a key component in predator-prey models, is frequently employed to describe the predation ability of predators. Grounded in experimental findings, Holling[15] developed three functional responses, which are described below:
I:mu,II:au1+mu,III:au21+mu2. |
In a specific area, we assume that the predation rate will reach saturation when the population of natural enemies is sufficiently large. This means that the predation rate will not increase further even if the number of natural enemies continues to grow. Conversely, when the population of natural enemies is low and begins to increase, the predation rate rises more rapidly than a linear function. This nonlinear increase is due to the fact that predators become more efficient at capturing prey as their numbers increase. A natural selection for such a predation rate is the Holling type-II functional response, which captures this nonlinear relationship between predator population and predation rate. In other words, the value of parameter α=1 in model (1.1).
In a relatively closed natural environment, the spatial distribution of predators and prey significantly influences population dynamics, resource allocation, and predation efficiency. The nonlocal competition is in the interaction of predators and prey in different spatial locations, so that the system can predict the population dynamics and competition results more accurately. Peng and Zhang[16] investigated a predator-prey model incorporating collective behavior and nonlocal competition among prey. The findings indicated that nonlocal competition had a destabilizing effect on the predator-prey system.
In addition to geographical distribution, ecological conditions, and other factors, time delay also plays an important role in the maintenance of ecological balance. In the predator-prey model, gestation delay is a key biological factor affecting the system, which is mainly reflected in the time difference between the occurrence of predation behavior and the birth of offspring. This physiological trait can significantly change the functional response pattern of predators to prey: During the breeding interval, the predator's predation frequency may decrease significantly or decrease to zero. This time delay mechanism directly affects the predator's growth rate by adjusting the number of effective predation per unit time and affects the dynamic balance of the ecosystem. The researchers in [17,18,19] developed a type of predator-prey model incorporating gestation delay and examined the dynamic characteristics of the systems.
Inspired by the above, we incorporate the nonlocal competition and gestation delay into the model (1.1). In the ecological environment, spatial distribution is often inhomogeneous, and spatial diffusion often occurs within populations. Therefore, when we study predator-prey models, reaction-diffusion equations may be more realistic. Thus, the resulting system is given by:
{∂u(x,t)∂t=d1Δu+ru(1−˜uK)−acuv1+achu,x∈Ω,t>0,∂v(x,t)∂t=d2Δv+gacu(x,t−τ)v(x,t−τ)1+ahcu(x,t−τ)−dv,x∈Ω,t>0,∂u(x,t)∂→n=0,∂v(x,t)∂→n=0,x∈∂Ω,t>0,u(x,t)=u0(x,t)≥0,v(x,t)=v0(x,t)≥0,(t,x)∈[−τ,0]ׯΩ, | (1.2) |
where u and v denote the density of Dendrolimus superans (prey) and Cyanopica cyanus (predator), respectively, the parameters r, K, h, c, and d have the same meanings as in model (1.1). d1 stands for the diffusion coefficients of Dendrolimus superans. d2 stands for the diffusion coefficients of Cyanopica cyanus. g denotes the efficiency with which energy is transferred from the species Dendrolimus superans to Cyanopica cyanus. a is the attack rate of predator on prey. τ is the gestation delay of Cyanopica cyanus. r, K, a, c, h, g, d, d1, d2 are a positive constant. We select Ω∈(0,lπ) where l>0. ˜u=1K∫ΩG(x,y)u(y,t)dy represents the nonlocal competition, and the kernel function is given by G(x,y)=1|Ω|=1lπ, which is based on the assumption that the competition intensity among prey individuals in the habitat is uniform, meaning that the competition between any two preys is identical. The Neumann boundary condition is employed in this study, suggesting that the habitat is closed and effectively preventing any prey or predator from entering or leaving, thereby maintaining a self-contained ecosystem. We aim to investigate the dynamics of a predator-prey model, with a particular focus on the stability and dynamic properties of the system as the time delay parameter varies and serves as the bifurcation parameter.
The structure of this paper is as follows: In Section 2, we analyze the stability of positive constant steady states and the existence of Hopf bifurcation. In Section 3, we investigate the normal form of the Hopf bifurcation. In Section 4, we present numerical simulations. Finally, conclusions are drawn in Section 5.
System (1.2) has a boundary equilibria E0=(0,0) and a non-trivial equilibrium E1=(u∗,v∗), where
u∗=d(g−hd)ac,v∗=rg(g−hd)ac(1−u∗K). |
If the following assumption holds:
(H0)g>hd, |
then the system (1.2) must have a positive constant steady equilibrium E1=(u∗,v∗).
By defining U(x,t)=(u(x,t),v(x,t))T, the linearized system for Eq (1.2) can be re-expressed as a differential equation at the equilibrium E=(u0,v0),with(u0,v0)=(0,0)or(u∗,v∗):
∂∂tU=D(Δu(x,t)Δv(x,t))+L1(u(x,t)v(x,t))+L2(u(x,t−τ)v(x,t−τ))+L3(˜u(x,t)˜v(x,t)), |
where
D=(d100d2),L1=(a1a20−d),L2=(00b1b2),L3=(c1000), |
with a1=r(1−u0K)−acv0(1+achu0)2,a2=−acu01+achu0,b1=gacv0(1+achu0)2,b2=gacu01+achu0,c1=−ru0K.
Especially, when (u0,v0)=(u∗,v∗), a1=r(1−u∗K)hdg>0,a2=−dg<0,b1=r(g−hd)(1−u∗K)>0,b2=d>0,c1=−ru∗K<0.
Hence, the characteristic equation of (1.2) at E=(u0,v0) is given as follows:
λ2+Anλ+(Bnλ+Cn)e−λτ+Dn=0,n=0,1,2⋯. | (2.1) |
where
{An=(nl)2(d1+d2)+d−a1−δnc1,Bn=−b2,Cn=−(nl)2b2d1+a1b2−a2b1+δnb2c1,Dn=(nl)4d1d2+(nl)2d1d−(nl)2a1d2−a1d−δnc1d, |
with
δn={1,n=0,0,n≠0. |
When τ=0, Eq (2.1) for equilibrium E0=(0,0) becomes
λ2+[n2l2(d1+d2)+d−r]λ+n4l4d1d2+n2l2d1d−n2l2rd2−rd=0,n=0,1,2⋯. | (2.2) |
For the case of n=0 in Eq (2.2), the product of the two eigenvalues −rd is negative. Therefore, the equilibrium E0=(0,0) is always unstable.
When τ=0, Eq (2.1) for equilibrium E1=(u∗,v∗) becomes
λ2+(An+Bn)λ+Cn+Dn=0,n=0,1,2⋯. | (2.3) |
Subsequently, we examine the conditions under which habitat complexity guarantees the stability of a positive constant steady state in the system (1.2).
An+Bn=(nl)2(d1+d2)−a1. Due to d1+d2>0, there is An+Bn>A1+B1>A0+B0=−(a1+c1). Assuming A0+B0=−(a1+c1)>0, there is c<hd+gahK(g−hd). So we have A1+B1=d1+d2l2−a1>0⇒d1+d2l2−rhdg+rhd2gk(g−hd)ac>0. Thus, if rhdl2−(d1+d2)g>0, that is c<rhd2l2Ka(g−hd)[rhdl2−(d1+d2)g]. Otherwise, if rhdl2−(d1+d2)g<0, that is c>0. Define:
c0={rhd2l2Ka(g−hd)[rhdl2−(d1+d2)g],rhdl2−(d1+d2)g>0,hd+gahK(g−hd),rhdl2−(d1+d2)g<0. |
Due to a1>0,a2<0,b1>0,b2>0,C0+D0=−a2b1>0 holds. When n=0, −a2b1>0, a12d1≥0 and △1=(a1d2)2+4a2b1d1d2<0 ⇒c<dk(g−hd)a(1−4d1(g−hd)rh)−1≜c∗, the function Cn+Dn=(nl)4d1d2−(nl)2a1d2−a2b1>0 holds for any n∈N.
In summary, if c<min{hd+gahK(g−hd),c0,c∗} holds, A0−B0>0,An−Bn>0,Cn+Dn>0, for n∈N holds. Thus, we make the following hypothesis
(H1)c<min{hd+gahK(g−hd),c0,c∗}. |
When (H1) holds, the roots of characteristic equation (2.3) have negative real parts.
Theorem 1. For the model (1.2) with τ=0, the stability findings for equilibria are detailed below:
1) Equilibrium E0=(0,0) is always unstable.
2) Equilibrium E1=(u∗,v∗) is always locally asymptotically stable when (H0) and (H1) hold.
3) Equilibrium E1=(u∗,v∗) is always unstable when (H0) or (H1) does not hold.
Next, we investigate the existence of bifurcating periodic solutions near the positive constant steady state E1=(u∗,v∗) for τ≠0.
When τ≠0, the characteristic equation describing the system (2.1) is presented as:
λ2+Anλ+(Bnλ+Cn)e−λτ+Dn=0,n=0,1,2⋯. | (2.4) |
We may assume that λ=±iω (ω>0) are a pair of purely imaginary roots of Eq (2.4). By substituting λ=±iω into Eq (2.4) and separating the real and imaginary components, we derive:
{−ω2+Dn+Cncos(ωτ)−Bnωsin(ωτ)=0,ωAn−Cnsin(ωτ)−Bnωcos(ωτ)=0, |
that is,
{cos(ωτ)=ω2(−AnBn+Cn)−DnCnC2n+B2nω2,sin(ωτ)=ω(AnCn+BnDn+Bnω2)C2n+B2nω2, | (2.5) |
with n=0,1,2⋯. Then, for n=0,1,2,3⋯ and j=0,1,2,3⋯, we get
τ(j)n={1ωnarccos(cosωτ)+2jπ,sinωτ≥0,1ωn[2π−arccos(cosωτ)]+2jπ,sinωτ<0. | (2.6) |
From (2.5), let z=ω2, we obtain:
h(z)=z2+(A2n−2Dn−B2n)z+D2n−C2n=0. | (2.7) |
Calculating the transversality condition, we get:
Re(dλdτ)−1|τ=τ(j)n=2z+(A2n−2Dn−B2n)C2n+B2nω2n=h′(z)C2n+B2nω2n. |
Denote
τ∗c=min{τ(0)n∣n∈N+} | (2.8) |
and
(H2)D2n−C2n<0, |
(H3)A2n−2Dn−B2n<0,D2n−C2n>0,Δn>0, |
with Δn=(A2n−2Dn−B2n)2−4(D2n−C2n).
We define the following set
G1={nkj∈N+|j=1,2,3⋯}, |
G2={nkt∈N+|t=1,2,3⋯}. |
G1 satis (H2) and G2 satis (H3), respectively.
When (H2) holds, Eq (2.7) has the unique positive root znk for some n=nkj∈G1. Therefore, we can solve for ωnk and τ(j)nk, where
ωnk=√12[−[A2nk−2Dnk−B2nk])+√Δnk], | (2.9) |
h′(znk)>0,so we haveRe(dλdτ1)−1|τ=τ(j)nk>0.
When (H3) holds, Eq (2.7) has two positive root znt,i for some n=nkt∈G2. Therefore, we can solve for ωnt,i and τ(j)nt,i,i=1,2, where
ωnt,i=√12[−(A2nt,i−2Dnt,i−B2nt,)∓√Δnt,i]. | (2.10) |
Due to ωnt,1<ωnt,2, we have h′(znt,1)<0 and h′(znt,2)>0. Thus Re(dλdτ)−1|τ=τ(j)nt,1<0, Re(dλdτ)−1|τ=τ(j)nt,2>0 hold.
In summary, we can get the following conclusions.
Theorem 2. Under the framework of model (1.2) with τ≥0, when (H0) and (H1) are valid and τ(j)n is defined by Eq (2.6), the subsequent conclusions hold.
1) Under the conditions G1=∅ and G2=∅,Eq (2.7) has no positive roots, and the positive constant steady state E1 retains local asymptotic stability for all τ≥0.
2) Under the conditions G1≠∅ and G2=∅,Eq (2.7) admits a unique positive root znk for some nk∈G1, the positive constant steady state E1 of system (1.2) exhibits asymptotic stability for 0<τ1<τ∗c and unstable for τ1>τ∗c, where τ∗c=min{τ(0)nk∣nk∈G1}. Additionally, system (1.2) undergoes nk−mode Hopf bifurcation near E1 when τ=τ(j)nk(nk∈G1,j=0,1,2,3⋯).
3) Under the conditions G1=∅ and G2≠∅,Eq (2.7) admits two positive roots znt,i(i=1,2) for some nt∈G2, the positive constant steady state E1 of system (1.2) exhibits asymptotic stability for 0<τ1<τ∗c, but a stability switch may occur for τ1>τ∗c, where τ∗c=min{τ(0)nt∣nt∈G1}. Furthermore, nt−mode Hopf bifurcation emerges near E1 at τ=τ(j)nt(nt∈G1,j=0,1,2,3⋯).
4) Under the conditions G1≠∅ and G2≠∅,Eq (2.7) admits positive roots znk and znt,i(i=1,2) and letting np correspond to the smallest critical time delay τ∗c, where np∈G1 or np∈G2, the positive constant steady state E1 of model (1.2) remains asymptotically stable for 0<τ1<τ∗c, but a stability switch may arise for τ1>τ∗c, where τ∗c=min{τ(0)np∣np∈G1ornp∈G2}. Furthermore, np−mode Hopf bifurcation occurs near E1 at τ=τ(j)np(np∈G1ornp∈G2,j=0,1,2,3⋯).
In this section, we use the multiple time scales method to derive the normal form of the Hopf bifurcation for system (1.2).
Suppose that the characteristic equation (2.4) has a pair of pure imaginary roots λ=±iω for τ=τc Then, system (1.2) undergoes n-mode Hopf bifurcation near the equilibrium point E1. Then, we derive the normal form of Hopf bifurcation of system (1.2) by the multiple time scales method. We choose time delay τ as a bifurcation parameter, where τ=τc+εμ. The parameter ε is a dimensionless scaling factor, μ is a perturbation parameter, and τc is given in Eq (2.8).
We let u(x,t)⟶u(x,t)−u∗, v(x,t)⟶v(x,t)−v∗, α=ac, then model (1.2) can be rewritten as
{∂u(x,t)∂t=d1Δu+u(r−f1−u∗K)−ru∗K˜u−f2v−12f11u2−f12uv−16f111u3−12f112u2v,∂v(x,t)∂t=d2Δu+gf2v(x,t−τ)+gf1u(x,t−τ)+g2f11u2(x,t−τ)+gf12u(x,t−τ)v(x,t−τ)+g6f111u3(x,t−τ)+g2f112u2(x,t−τ)v(x,t−τ)−dv, | (3.1) |
where
f1=αv∗(1+αhu∗)2,f2=αu∗1+αhu∗,f11=−2α2hv∗(1+αhu∗)3+rK,f12=α(1+αhu∗)2,f111=6α3h2v∗(1+αhu∗)4,f112=−2α2h(1+αhu∗)3. |
Let h=(h11,h12)T be the the eigenvector of the linear operator of system (3.1) corresponding to the eigenvalue λ=iω, and let h∗=(h∗11,h∗12)T be the normalized eigenvector of the adjoint operator of the linear operator of system (3.1) corresponding to the eigenvalue −iω satisfying the inner product <h∗, h>=¯h∗T⋅h=1. By a simple calculation, we get
h=(h11,h12)T=(1,−iω−(nl)2d1+r−f1−u∗K−u∗Kδnf2),h∗=s(h21,h22)T=s(f2iω−(nl)2d1+r−f1−u∗K−u∗Kδn,1), | (3.2) |
with s=(¯h11h21+h22¯h12)−1, and
δn={1,n=0,0,n≠0. |
Suppose the solution of Eq (3.1) is
U(x,t)=U(x,T0,T1,T2,⋯)=+∞∑k=1εkUk(x,T0,T1,T2,⋯), | (3.3) |
where
U(x,T0,T1,T2,⋯)=(u(x,T0,T1,T2,⋯),v(x,T0,T1,T2,⋯))T,Uk(x,T0,T1,T2,⋯)=(uk(x,T0,T1,T2,⋯),vk(x,T0,T1,T2,⋯))T. |
The derivation with respect to t is
ddt=∂∂T0+ε∂∂T1+ε2∂∂T2+⋯=D0+εD1+ε2D2+⋯, |
where the differential operator Di=∂∂Ti,i=0,1,2,⋯.
We obtain
∂U(x,t)∂t=εD0U1+ε2D0U2+ε2D1U1+ε3D0U3+ε3D1U2+ε3D2U1+⋯,ΔU(x,t)=εΔU1(x,t)+ε2ΔU2(x,t)+ε3ΔU3(x,t)+⋯. | (3.4) |
Denote
uj=uj(x,T0,T1,T2,⋯),vj=vj(x,T0,T1,T2,⋯),uj,τc=uj(x,T0−τc,T1,T2,⋯),vj,τc=vj(x,T0−τc,T1,T2,⋯), |
with j=1,2,3,⋯.
We take perturbations as τ=τc+εμ to deal with the delayed terms. By expand U(x,t−τ) at U(x,T0−τc,T1,T2,···), respectively, that is,
{u(x,t−τ)=εu1,τc+ε2u2,τc+ε3u3,τc−ε2μD0u1,τc−ε3μD0u2,τc−ε2τcD1u1,τc−ε3μD1u1,τc−ε3τcD2u1,τc−ε3τcD1u2,τc+⋯,v(x,t−τ)=εv1,τc+ε2v2,τc+ε3v3,τc−ε2μD0v1,τc−ε3μD0v2,τc−ε2τcD1v1,τc−ε3μD1v1,τc−ε3τcD2v1,τc−ε3τcD1v2,τc+⋯. | (3.5) |
By substituting Eqs (3.3)–(3.5) into Eq (3.1), we obtain the expression for ε.
{D0u1−d1Δu1−(r−f1−u∗K)u1+u∗K~u1+f2v1=0,D0v1−d2Δv1−gf2v1,τc−gf1u1,τc+dv1=0. | (3.6) |
The solution of Eq (3.6) can be written as follows:
{u1=GeiωτcT0h11cos(nx)+c.c.,v1=GeiωτcT0h12cos(nx)+c.c., | (3.7) |
where h11 and h12 are given in Eq (3.2), and c.c. means the complex conjugate of the preceding terms.
For the ε2, we have
{D0u2−d1u2−(r−f1−u∗K)u2+u∗K~u2+f2v2=−D1u1−~u1v1K−12f11u21−f12u1v1,D0v2−d2v2−gf2v2,τc−gf1u2,τc+dv2=−D1v1+gf2(τcD1v1,τc+μD0v1,τc)+gf1(τcD1u1,τc+μD0u1,τc)+g2f11u21,τc+gf12u1,τcv1,τc. | (3.8) |
Substituting Eq (3.7) into the right side of Eq (3.8), we denote the coefficient vector of eiωT0 as m1, from solvability condition <h∗,(m1,cosnlx)>=0, we obtain
∂G∂T1=μMG, | (3.9) |
with
M=iω(gf2h12+gf1h11)[−iω−n2l2d1+r−f1−u∗K(1−δn)]f2h11+(h12+τcgf2h12+τcgf1h11)[−iω−n2l2d1+r−f1−u∗K(1−δn)]. |
Assume the solution of Eq (3.8) to be as follows:
{u2=+∞∑k=0(η0kG¯G+η1kG2e2iωT0+¯η1k¯G2e−2iωT0)cos(kxl),v2=+∞∑k=0(ς0kG¯G+ς1kG2e2iωT0+¯ς1k¯G2e−2iωT0)cos(kxl). | (3.10) |
Denote
{ck=∫lπ0cos(nxl)cos(kxl)dx={lπ,k=n≠0,lπ2,k=n=0,0,k≠n.fk=∫lπ0cos2(nxl)cos(kxl)dx={lπ2,k=0,lπ4,k=2n≠0,0,k≠2n≠0. |
Substituting solutions Eqs (3.7) and (3.10) into Eq (3.8), we obtain
η0k=X0kD0k−Y0kB0kA0kD0k−C0kB0k,ζ0k=A0kY0k−C0kX0kA0kD0k−C0kB0k,η1k=X1kD1k−Y1kB1kA1kD1k−C1kB1k,ζ1k=A1kY1k−C1kX1kA1kD1k−C1kB1k, |
where
{A0k=[(kl)2d1−(r−f1−u∗K)]∫lπ0cos2(klx)dx+u∗klπ[∫lπ0cos2(klx)dx]2,B0k=f2∫lπ0cos2(klx)dx,C0k=−gf1∫lπ0cos2(klx)dx,D0k=(d1+d2−gf2)∫lπ0cos2(klx)dx,X0k=−[(h11¯h12+h12¯h11)f2+f11h11¯h11+(h11¯h12+h11h12)]fk,Y0k=g[f11h11¯h11+f12(h12¯h11+h11¯h12)]fk,A1k=[2iω+(kl)2d1−(r−f1−u∗K)]∫lπ0cos2(klx)dx+u∗klπ[∫lπ0cos2(klx)dx]2,B1k=f2∫lπ0cos2(klx)dx,C1k=−gf1∫lπ0cos2(klx)dx,D1k=[2iω+d2(kl)2−gf2+d1]∫lπ0cos2(klx)dx,X1k=−h11h12ck−(12f11h211+f2h11h12)fk,Y1k=(g2f11h211+gf12h12h11)fk. |
For the ε3, we obtain
{D0u3−d1u3−(r−f1−u3K)u3+u3K~u3+f2v3+16f111u33=−D2u1−D1u2−~u1v2+~u2v1K−f11(u1u2+u2v1)−16f111u31−12f112u21v1+o(μ),D0v3−d2v3+gf2v3,τc+dv3=−D1u2−D2u1−gf2τc(D2v1,τc+D1v2,τc)−gf1τc(D2u1,τc+D1u2,τc)+gf11(u2,τcu1,τc−u1D1u1,τcτc)++g6f11u31,τc+g2f11u21,τ1v1,τc+gf12[u1,τcv2,τc+u2,τcv1,τc−τc(D1u1,τcv1,τc+D1v1,τcv1,τc)]+o(μ). | (3.11) |
Substituting Eqs (3.7) and (3.10) into the right side of Eq (3.11), we denote the coefficient vector of eiωT0 as m2, by solvability condition <h∗,(m2,cosnlx)>=0, we obtain
∂G∂T2=XG2¯G, | (3.12) |
where
X=σφ, | (3.13) |
with
{σ=−∞∑k=01klπ(η0kh11+η1k¯h11)fk+∞∑k=0(f11η0kh11+f11η1k¯h11+f12ς0kh12+f12ς1k¯h12)ck−12[(1−g)f111h211¯h11+(f112−gf111)(h211¯h12+2h11¯h11h12)]∫lπ0cos3(nlx)dx+∞∑k=0g[f11(η0kh11+η1k¯h11)+f12(ς0kh11+ς1k¯h11+η0kh12+η1k¯h12)]ck,φ=−[2h11+gτc(f2h12+f1h11)]∫lπ0cos2(nlx)dx. |
According to the above analysis, the normal form of Hopf bifurcation for system (1.2) reduced on the center manifold is
˙G=MμG+XG2¯G, | (3.14) |
where M and X are given by Eqs (3.9) and (3.13), respectively.
Let G=reiθ and substitute it into Eq (3.14), and we obtain the Hopf bifurcation normal form in polar coordinates:
{˙r=Re(M)μr+Re(X)r3,˙θ=Im(M)μ+Im(X)r2. | (3.15) |
Therefore, we arrive at the following theorem.
Theorem 3. For system (3.15), if Re(M)μRe(X)<0 holds, model (1.2) exists periodic solutions near equilibrium E1=(u∗,v∗).
1) If Re(M)μ<0 the bifurcating periodic solutions reduced on the center manifold are unstable, and the direction of bifurcation is forward (backward) for μ>0(μ<0).
2) If Re(M)μ>0 the bifurcating periodic solutions reduced on the center manifold are stable, and the direction of bifurcation is forward (backward) for μ>0(μ<0).
In this section, we perform numerical simulations to verify the correctness of the theoretical analysis. In summary, we choose d=0.3,g=0.6,a=0.6,d1=0.01,d2=0.2,c=0.55, r=0.41, K=5, h=0.41, and l=1.
Based on the data above, (H0) and (H1) always hold, and system (1.2) has one unstable boundary equilibrium E0=(0,0), and one nontrivial equilibrium E1=(u∗,v∗)=(1.90585,0.96710). What matters most to us is the stability of the nontrivial equilibrium E1.
According to Theorem 1, then E1 is local asymptotically stable. This means that if system (1.2) is without delay, although Cyanopica cyanus and Dendrolimus superans can coexist at this time, natural predators are capable of suppressing the reproduction of the pests.
When τ≠0, by a simple calculation, (H2) only holds for n=1 there does not exist any n such that (H3) holds. Thus, Eq (2.9) has a unique positive root ω=0.1616, which corresponds to the critical delay τ(0)1=2.5897. From the definition of τ∗c, we obtain τ∗c=2.5897, theorem 2.2 supports the conclusion that the positive constant steady state E1 achieves local asymptotic stability when τ∈[0,2.5897), and instability when τ∈(2.5897,+∞). We select τ=1.5∈[0,2.5897) to conduct the simulation. See Figure 3.
We choose τ=2.8>τ∗c=2.5879, from Eqs (3.9) and (3.12), we obtain Re(M)>0, Re(X)<0. Thus, according to Theorem 3, system (1.2) will generate inhomogeneous periodic solutions near the positive constant steady state E1 of model (1.2), and bifurcating periodic solutions are stable and forward (see Figure 4).
By analyzing Figures 3 and 4, we can draw the following conclusions.
1) When the gestation delay of the predator is less than the critical value, the predator can quickly control the number of pests and reach a stable state by preying on pests.
2) When the gestation delay of the predator is slightly more than the critical value, the predator has a certain control effect on the number of pests. This will cause the number of pest populations to erupt periodically, and the number of natural enemy populations will fluctuate periodically.
3) Comparing Figures 3 and 4, when the gestation delay of insectivorous birds is long, so it is necessary to artificially intervene in the population of pests to prevent the outbreak of insect pests. By releasing insectivorous birds to increase their number, we can indirectly reduce the increase in the number of pests and the outbreak of pests due to the prolonged pregnancy of predators, so that the population of pests can return to a controllable stable state.
In this paper, aiming at the population density control problem of the pine caterpillar, considering the Holling-II type functional response, we developed a pest control model with gestation delay and nonlocal competition. For our analysis, we focused on two major aspects: first, the existence and stability of the positive constant steady state, and second, the conditions under which Hopf bifurcations emerge near this steady state. In the part of numerical simulation, we selected a set of suitable parameters for numerical simulation. It provided an explanation for effectively controlling the population density of the pine caterpillar and maintained the stability between natural enemies and the pine caterpillar species, so as to realize effective environmental protection and true green pest control. Therefore, gestation delay has a significant impact on the stability of the population. When the gestation delay is less than the critical delay, the predator can effectively control the pest population. When the gestation delay exceeds the critical delay, the pest population experiences periodic outbreaks.
The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.
This study was funded by the Heilongjiang Provincial Natural Science Foundation of China (Grant No. LH2024A001), and the College Students Innovations Special Project funded by Northeast Forestry University (No. DCLXY-2025011).
The authors declare there are no conflicts of interest.
[1] | Moon TC, Befus AD, Kulka M (2014) Mast cell mediators: Their differential release and the secretory pathways involved. Front Immunol 5: 569. https://doi.org/10.3389/fimmu.2014.00569 |
[2] |
Theoharides TC, Kempuraj D, Tagen M, et al. (2007) Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 217: 65-78. https://doi.org/10.1111/j.1600-065X.2007.00519.x ![]() |
[3] |
Abraham SN, St John AL (2010) Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 10: 440-452. https://doi.org/10.1038/nri2782 ![]() |
[4] | He Y, Li Z, Alexander PG, et al. (2020) Pathogenesis of osteoarthritis: Risk factors, regulatory pathways in chondrocytes, and experimental models. Biology (Basel) 9: 1-32. https://doi.org/10.3390/biology9080194 |
[5] | Chow YY, Chin KY (2020) The role of inflammation in the pathogenesis of osteoarthritis. Mediators Inflamm 2020: 8293921. https://doi.org/10.1155/2020/8293921 |
[6] |
Sokolove J, Lepus CM (2013) Role of inflammation in the pathogenesis of osteoarthritis: Latest findings and interpretations. Ther Adv Musculoskelet Dis 5: 77-94. https://doi.org/10.1177/1759720X12467868 ![]() |
[7] |
Dean G, Hoyland JA, Denton J, et al. (1993) Mast cells in the synovium and synovial fluid in osteoarthrhis. Rheumatology 32: 671-675. https://doi.org/10.1093/rheumatology/32.8.671 ![]() |
[8] |
Wang Q, Lepus CM, Raghu H, et al. (2019) IgE-mediated mast cell activation promotes inflammation and cartilage destruction in osteoarthritis. Elife 8: e39905. https://doi.org/10.7554/eLife.39905 ![]() |
[9] |
Dan J, Izumi M, Habuchi H, et al. (2021) A novel mice model of acute flares in osteoarthritis elicited by intra-articular injection of cultured mast cells. J Exp Orthop 8: 75. https://doi.org/10.1186/s40634-021-00391-6 ![]() |
[10] |
Sellam J, Berenbaum F (2013) Is osteoarthritis a metabolic disease?. Joint Bone Spine 80: 568-573. https://doi.org/10.1016/j.jbspin.2013.09.007 ![]() |
[11] |
de Lange-Brokaar BJE, Kloppenburg M, Andersen SN, et al. (2016) Characterization of synovial mast cells in knee osteoarthritis: Association with clinical parameters. Osteoarthr Cartilage 24: 664-671. https://doi.org/10.1016/j.joca.2015.11.011 ![]() |
[12] |
Farinelli L, Aquili A, Mattioli-Belmonte M, et al. (2022) Synovial mast cells from knee and hip osteoarthritis: histological study and clinical correlations. J Exp Orthop 9: 13. https://doi.org/10.1186/s40634-022-00446-2 ![]() |
[13] | Ceponis A, Konttinen YT, Takagi M, et al. (1998) Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation. J Rheumatol 25: 2304-2314. |
[14] |
Dahlin JS, Hallgren J (2015) Mast cell progenitors: Origin, development and migration to tissues. Mol Immunol 63: 9-17. https://doi.org/10.1016/j.molimm.2014.01.018 ![]() |
[15] |
Gözel N, Çakirer M, Karataş A, et al. (2018) Sorafenib reveals anti-arthritic potentials in collagen induced experimental arthritis model. Arch Rheumatol 33: 309. https://doi.org/10.5606/ArchRheumatol.2018.6652 ![]() |
[16] |
Kulkarni P, Harsulkar A, Märtson AG, et al. (2022) Mast cells differentiated in synovial fluid and resident in osteophytes exalt the inflammatory pathology of osteoarthritis. Int J Mol Sci 2022: 541. https://doi.org/10.3390/ijms23010541 ![]() |
[17] | Aquili A, Farinelli L, Bottegoni C, et al. (2017) The effect of anti-IgE therapy in knee osteoarthritis: a pilot observational study. J Biol Regul Homeost Agents 31: 1-5. |
[18] |
Theoharides TC, Alysandratos KD, Angelidou A, et al. (2012) Mast cells and inflammation. Biochim Biophys Acta Mol Cell Res 1822: 21-33. https://doi.org/10.1016/j.bbadis.2010.12.014 ![]() |
[19] | Bax HJ, Keeble AH, Gould HJ (2012) Cytokinergic IgE action in mast cell activation. Front Immunol 3: 229. https://doi.org/10.3389/fimmu.2012.00229 |
[20] |
Park S, Choi NK (2020) Association between serum immunoglobulin E levels and knee osteoarthritis in Korean adults. Osteoarthr Cartilage 28: 462-467. https://doi.org/10.1016/j.joca.2020.02.830 ![]() |
[21] |
Nishioka M, Ioi H, Matsumoto R, et al. (2008) TMJ osteoarthritis/osteoarthrosis and immune system factors in a Japanese sample. Angle Orthod 78: 793-798. https://doi.org/10.2319/091407-438 ![]() |
[22] |
Riegger J, Brenner RE (2020) Pathomechanisms of posttraumatic osteoarthritis: chondrocyte behavior and fate in a precarious environment. Int J Mol Sci 21: 1560. https://doi.org/10.3390/ijms21051560 ![]() |
[23] |
Foell D, Wittkowski H, Roth J (2007) Mechanisms of disease: A ‘DAMP’ view of inflammatory arthritis. Nat Clin Pract Rheumatol 3: 382-390. https://doi.org/10.1038/ncprheum0531 ![]() |
[24] |
Sandig H, Bulfone-Paus S (2012) TLR signaling in mast cells: common and unique features. Front Immunol 3: 185. https://doi.org/10.3389/fimmu.2012.00185 ![]() |
[25] |
Gondokaryono SP, Ushio H, Niyonsaba F, et al. (2007) The extra domain A of fibronectin stimulates murine mast cells via Toll-like receptor 4. J Leukocyte Biol 82: 657-665. https://doi.org/10.1189/jlb.1206730 ![]() |
[26] |
Park H, Hong J, Yin Y, et al. (2020) TAP2, a peptide antagonist of Toll-like receptor 4, attenuates pain and cartilage degradation in a monoiodoacetate-induced arthritis rat model. Sci Rep 10: 1-13. https://doi.org/10.1038/s41598-020-74544-5 ![]() |
[27] |
Flannery CR, Zollner R, Corcoran C, et al. (2009) Prevention of cartilage degeneration in a rat model of osteoarthritis by intraarticular treatment with recombinant lubricin. Arthritis Rheum 60: 840-847. https://doi.org/10.1002/art.24304 ![]() |
[28] |
Alquraini A, Garguilo S, D'Souza G, et al. (2015) The interaction of lubricin/proteoglycan 4 (PRG4) with Toll-like receptors 2 and 4: an anti-inflammatory role of PRG4 in synovial fluid. Arthritis Res Ther 17: 1-12. https://doi.org/10.1186/s13075-015-0877-x ![]() |
[29] |
Sick E, Brehin S, André P, et al. (2010) Advanced glycation end products (AGEs) activate mast cells. Brit J Pharmacol 161: 442-455. https://doi.org/10.1111/j.1476-5381.2010.00905.x ![]() |
[30] |
Swanson KV, Deng M, Ting JPY (2019) The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol 2019 198 19: 477-489. https://doi.org/10.1038/s41577-019-0165-0 ![]() |
[31] |
McAllister MJ, Chemaly M, Eakin AJ, et al. (2018) NLRP3 as a potentially novel biomarker for the management of osteoarthritis. Osteoarthr Cartilage 26: 612-619. https://doi.org/10.1016/j.joca.2018.02.901 ![]() |
[32] | Guo X, Xu X, Li T, et al. (2021) NLRP3 inflammasome activation of mast cells by estrogen via the nuclear-initiated signaling pathway contributes to the development of endometriosis. Front Immunol 12: 3909. https://doi.org/10.3389/fimmu.2021.749979 |
[33] |
Wang Q, Rozelle AL, Lepus CM, et al. (2011) Identification of a central role for complement in osteoarthritis. Nat Med 17: 1674. https://doi.org/10.1038/nm.2543 ![]() |
[34] |
Gaudenzio N, Sibilano R, Marichal T, et al. (2016) Different activation signals induce distinct mast cell degranulation strategies. J Clin Invest 126: 3981. https://doi.org/10.1172/JCI85538 ![]() |
[35] |
Elieh Ali Komi D, Shafaghat F, Kovanen PT, et al. (2020) Mast cells and complement system: Ancient interactions between components of innate immunity. Allergy 75: 2818-2828. https://doi.org/10.1111/all.14413 ![]() |
[36] |
Schäfer B, Piliponsky AM, Oka T, et al. (2013) Mast cell anaphylatoxin receptor expression can enhance IgE-dependent skin inflammation in mice. J Allergy Clin Immunol 131: 541-548. https://doi.org/10.1016/j.jaci.2012.05.009 ![]() |
[37] |
Lubbers R, van Essen MF, van Kooten C, et al. (2017) Production of complement components by cells of the immune system. Clin Exp Immunol 188: 183-194. https://doi.org/10.1111/cei.12952 ![]() |
[38] |
Bollmann M, Colombo F, Marco P, et al. (2018) Inhibition of the complement system component C5 as possible treatment in OA. Osteoarthr Cartilage 26: S108. https://doi.org/10.1016/j.joca.2018.02.236 ![]() |
[39] |
Yu C, Zang H, Yang C, et al. (2021) Study of chondroitin sulfate E oligosaccharide as a promising complement C5 inhibitor for osteoarthritis alleviation. Mat Sci Eng C-Bio S 127: 112234. https://doi.org/10.1016/j.msec.2021.112234 ![]() |
[40] |
Sousa-Valente J, Calvo L, Vacca V, et al. (2018) Role of TrkA signalling and mast cells in the initiation of osteoarthritis pain in the monoiodoacetate model. Osteoarthr Cartilage 26: 84-94. https://doi.org/10.1016/j.joca.2017.08.006 ![]() |
[41] |
Obara I, Telezhkin V, Alrashdi I, et al. (2020) Histamine, histamine receptors, and neuropathic pain relief. Brit J Pharmacol 177: 580. https://doi.org/10.1111/bph.14696 ![]() |
[42] |
Miller RE, Block JA, Malfait AM (2017) Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?. Curr Opin Rheumatol 29: 110-118. https://doi.org/10.1097/BOR.0000000000000354 ![]() |
[43] |
Nwosu LN, Mapp PI, Chapman V, et al. (2016) Extended report: Blocking the tropomyosin receptor kinase A (TrkA) receptor inhibits pain behaviour in two rat models of osteoarthritis. Ann Rheum Dis 75: 1246. https://doi.org/10.1136/annrheumdis-2014-207203 ![]() |
[44] |
Okamura Y, Mishima S, Kashiwakura J, et al. (2017) The dual regulation of substance P-mediated inflammation via human synovial mast cells in rheumatoid arthritis. Allergol Int 66: S9-S20. https://doi.org/10.1016/j.alit.2017.03.002 ![]() |
[45] |
Henry CH, Wolford LM (2001) Substance P and mast cells: Preliminary histologic analysis of the human temporomandibular joint. Oral Surg Oral Med O 92: 384-389. https://doi.org/10.1067/moe.2001.117811 ![]() |
[46] |
Green DP, Limjunyawong N, Gour N, et al. (2019) A mast-cell-specific receptor mediates neurogenic inflammation and pain. Neuron 101: 412-420. https://doi.org/10.1016/j.neuron.2019.01.012 ![]() |
[47] |
Ko KR, Lee H, Han SH, et al. (2022) Substance P, a promising therapeutic target in musculoskeletal disorders. Int J Mol Sci 23: 2583. https://doi.org/10.3390/ijms23052583 ![]() |
[48] |
Ogasawara H, Noguchi M (2021) Therapeutic potential of MRGPRX2 inhibitors on mast cells. Cells 10: 2096. https://doi.org/10.3390/cells10112906 ![]() |
[49] |
Thangam EB, Jemima EA, Singh H, et al. (2018) The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: The hunt for new therapeutic targets. Front Immunol 9: 1873. https://doi.org/10.3389/fimmu.2018.01873 ![]() |
[50] |
Shirinsky I, Shirinsky V (2018) H1-antihistamines are associated with lower prevalence of radiographic knee osteoarthritis: a cross-sectional analysis of the Osteoarthritis Initiative data. Arthritis Res Ther 20: 1-6. https://doi.org/10.1186/s13075-018-1619-7 ![]() |
[51] |
Bihlet AR, Miller CP, Byrjalsen I, et al. (2022) OP0230 antihistamine use and structural progression of knee OA: a post-hoc analysis of two phase III clinical trials. Ann Rheum Dis 81: 152. https://doi.org/10.1136/annrheumdis-2022-eular.4425 ![]() |
[52] |
Sommer C (2010) Serotonin in pain and pain control. Handbook of Behavioral Neuroscience . Amsterdam: Elsevier 457-471. https://doi.org/10.1016/S1569-7339(10)70096-5 ![]() |
[53] |
Harbuz MS, Perveen-Gill Z, Lalies MD, et al. (1996) The role of endogenous serotonin in adjuvant-induced arthritis in the rat. Rheumatology 35: 112-116. https://doi.org/10.1093/rheumatology/35.2.112 ![]() |
[54] |
Kopp S, Alstergren P (2002) Blood serotonin and joint pain in seropositive versus seronegative rheumatoid arthritis. Mediators Inflamm 11: 211. https://doi.org/10.1080/09629350290000069 ![]() |
[55] |
Wan M, Ding L, Wang D, et al. (2020) Serotonin: A potent immune cell modulator in autoimmune diseases. Front Immunol 11: 186. https://doi.org/10.3389/fimmu.2020.00186 ![]() |
[56] |
Seidel MF, Fiebich BL, Ulrich-Merzenich G, et al. (2008) Serotonin mediates PGE2 overexpression through 5-HT2A and 5-HT3 receptor subtypes in serum-free tissue culture of macrophage-like synovial cells. Rheumatol Int 28: 1017-1022. https://doi.org/10.1007/s00296-008-0564-1 ![]() |
[57] |
Stevens RL, Adachi R (2007) Protease-proteoglycan complexes of mouse and human mast cells and importance of their β-tryptase-heparin complexes in inflammation and innate immunity. Immunol Rev 217: 155-167. https://doi.org/10.1111/j.1600-065X.2007.00525.x ![]() |
[58] |
So AK, Varisco PA, Kemkes-Matthes B, et al. (2003) Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 1: 2510-2515. https://doi.org/10.1111/j.1538-7836.2003.00462.x ![]() |
[59] | Chou PY, Su CM, Huang CY, et al. (2014) The characteristics of thrombin in osteoarthritic pathogenesis and treatment. Biomed Res Int 2014: 1-9. https://doi.org/10.1155/2014/407518 |
[60] | Migliore A, Procopio S (2015) Effectiveness and utility of hyaluronic acid in osteoarthritis. Clin Cases Miner Bone Metab 12: 31. https://doi.org/10.11138/ccmbm/2015.12.1.031 |
[61] |
Bishnoi M, Jain A, Hurkat P, et al. (2016) Chondroitin sulphate: a focus on osteoarthritis. Glycoconj J 33: 693-705. https://doi.org/10.1007/s10719-016-9665-3 ![]() |
[62] |
Takano H, Furuta K, Yamashita K, et al. (2012) Restriction of mast cell proliferation through hyaluronan synthesis by co-cultured fibroblasts. Biol Pharm Bull 35: 408-412. https://doi.org/10.1248/bpb.35.408 ![]() |
[63] |
Theoharides TC, Patra P, Boucher W, et al. (2000) Chondroitin sulphate inhibits connective tissue mast cells. Brit J Pharmacol 131: 1039. https://doi.org/10.1038/sj.bjp.0703672 ![]() |
[64] | Crivellato E, Beltrami CA, Mallardi F, et al. (2004) The mast cell: an active participant or an innocent bystander?. Histol Histopathol 19: 259-270. |
[65] |
Buckley MG, Gallagher PJ, Walls AF (1998) Mast cell subpopulations in the synovial tissue of patients with osteoarthritis: selective increase in numbers of tryptase-positive, chymase-negative mast cells. J Pathol 186: 67-74. https://doi.org/10.1002/(SICI)1096-9896(199809)186:1<67::AID-PATH132>3.0.CO;2-D ![]() |
[66] |
Takata K, Uchida K, Mukai M, et al. (2020) Increase in tryptase and its role in the synovial membrane of overweight and obese patients with osteoarthritis of the knee. Diabetes Metab Syndr Obes 13: 1491-1497. https://doi.org/10.2147/DMSO.S253147 ![]() |
[67] |
Marquardt U, Zettl F, Huber R, et al. (2002) The crystal structure of human α1-tryptase reveals a blocked substrate-binding region. J Mol Biol 321: 491-502. https://doi.org/10.1016/S0022-2836(02)00625-3 ![]() |
[68] |
Buckley MG, Walters C, Wong WM, et al. (1997) Mast cell activation in arthritis: Detection of α- and β-tryptase, histamine and eosinophil cationic protein in synovial fluid. Clin Sci 93: 363-370. https://doi.org/10.1042/cs0930363 ![]() |
[69] |
Nakano S, Mishiro T, Takahara S, et al. (2007) Distinct expression of mast cell tryptase and protease activated receptor-2 in synovia of rheumatoid arthritis and osteoarthritis. Clin Rheumatol 26: 1284-1292. https://doi.org/10.1007/s10067-006-0495-8 ![]() |
[70] |
Xiang Y, Masuko-Hongo K, Sekine T, et al. (2006) Expression of proteinase-activated receptors (PAR)-2 in articular chondrocytes is modulated by IL-1β, TNF-α and TGF-β. Osteoarthr Cartilage 14: 1163-1173. https://doi.org/10.1016/j.joca.2006.04.015 ![]() |
[71] |
Huang X, Ni B, Xi Y, et al. (2019) Protease-activated receptor 2 (PAR-2) antagonist AZ3451 as a novel therapeutic agent for osteoarthritis. Aging 11: 12532. https://doi.org/10.18632/aging.102586 ![]() |
[72] |
Ferrell WR, Kelso EB, Lockhart JC, et al. (2010) Protease-activated receptor 2: a novel pathogenic pathway in a murine model of osteoarthritis. Ann Rheum Dis 69: 2051-2054. https://doi.org/10.1136/ard.2010.130336 ![]() |
[73] |
Lucena F, McDougall JJ (2021) Protease activated receptors and arthritis. Int J Mol Sci 22: 9352. https://doi.org/10.3390/ijms22179352 ![]() |
[74] |
Smith RL (1999) Degradative enzymes in osteoarthritis. Front Biosci 4: 704-712. https://doi.org/10.2741/A388 ![]() |
[75] |
Meszaros E, Malemud CJ (2012) Prospects for treating osteoarthritis: enzyme–protein interactions regulating matrix metalloproteinase activity. Ther Adv Chronic Dis 3: 219. https://doi.org/10.1177/2040622312454157 ![]() |
[76] | Crofford LJ, Sano H, Karalis K, et al. (1993) Corticotropin-releasing hormone in synovial fluids and tissues of patients with rheumatoid arthritis and osteoarthritis. J Immunol 151: 1587-1596. |
[77] |
Zhao Z, Li E, Cao Q, et al. (2016) Endothelin-1 concentrations are correlated with the severity of knee osteoarthritis. J Invest Med 64: 872-874. https://doi.org/10.1136/jim-2015-000030 ![]() |
[78] |
De Falco L, Fioravanti A, Galeazzi M, et al. (2013) Bradykinin and its role in osteoarthritis. Reumatismo 65: 97-104. https://doi.org/10.4081/reumatismo.2013.97 ![]() |
[79] |
Roy-Beaudry M, Martel-Pelletier J, Pelletier JP, et al. (2003) Endothelin 1 promotes osteoarthritic cartilage degradation via matrix metalloprotease 1 and matrix metalloprotease 13 induction. Arthritis Rheum 48: 2855-2864. https://doi.org/10.1002/art.11247 ![]() |
[80] |
Sin A, Tang W, Wen CY, et al. (2015) The emerging role of endothelin-1 in the pathogenesis of subchondral bone disturbance and osteoarthritis. Osteoarthr Cartilage 23: 516-524. https://doi.org/10.1016/j.joca.2014.11.002 ![]() |
[81] |
Khatib AM, Siegfried G, Messai H, et al. (2002) Mechanism of inhibition of endothelin-1-stimulated proteoglycan and collagen synthesis in rat articular chondrocytes. Cytokine 17: 254-261. https://doi.org/10.1006/cyto.2001.1001 ![]() |
[82] |
Au M, Liu Z, Rong L, et al. (2020) Endothelin-1 induces chondrocyte senescence and cartilage damage via endothelin receptor type B in a post-traumatic osteoarthritis mouse model. Osteoarthr Cartilage 28: 1559-1571. https://doi.org/10.1016/j.joca.2020.08.006 ![]() |
[83] |
Tenti S, Pascarelli NA, Cheleschi S, et al. (2016) The emerging role of bradykinin in the pathogenesis of osteoarthritis and its possible clinical implications. Curr Rheumatol Rev 12: 177-184. https://doi.org/10.2174/1573397112666160331143305 ![]() |
[84] |
Montjean R, Escaich S, Carelli C, et al. (2019) Chimeric peptide combining both growth hormone and somatostatin sequences (REG-O3) improves function and prevents cartilage degradation in rat model of osteoarthritis. Osteoarthr Cartilage 27: S428. https://doi.org/10.1016/j.joca.2019.02.449 ![]() |
[85] | Silveri F, Morosini P, Brecciaroli D, et al. (1994) Intra-articular injection of somatostatin in knee osteoarthritis: clinical results and IGF-1 serum levels. Int J Clin Pharmacol Res 14: 79-85. |
[86] |
Intekhab-Alam NY, White OB, Getting SJ, et al. (2013) Urocortin protects chondrocytes from NO-induced apoptosis: a future therapy for osteoarthritis?. Cell Death Discov 4: e717. https://doi.org/10.1038/cddis.2013.231 ![]() |
[87] |
Lawrence KM, Jones RC, Jackson TR, et al. (2017) Chondroprotection by urocortin involves blockade of the mechanosensitive ion channel Piezo1. Sci Rep 7: 1-12. https://doi.org/10.1038/s41598-017-04367-4 ![]() |
[88] |
Jiang W, Wang H, Li YS, et al. (2016) Role of vasoactive intestinal peptide in osteoarthritis. J Biomed Sci 23: 1-6. https://doi.org/10.1186/s12929-016-0280-1 ![]() |
[89] | Caughey GH, Leidig F, Viro NF, et al. (1988) Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J Pharmacol Exp Ther 244: 133-137. |
[90] |
Vincent TL (2019) IL-1 in osteoarthritis: Time for a critical review of the literature. F1000Research 8: 1-8. https://doi.org/10.12688/f1000research.18831.1 ![]() |
[91] | Florián AM (2011) IL-1 and its role in osteoarthritis. Open J Med 1: 1-6. |
[92] | Li H, Xie S, Qi Y, et al. (2018) TNF-αincreases the expression of inflammatory factors in synovial fibroblasts by inhibiting the PI3K/AKT pathway in a rat model of monosodium iodoacetate-induced osteoarthritis. Exp Ther Med 16: 4737-4744. https://doi.org/10.3892/etm.2018.6770 |
[93] |
Hu G, Zhao X, Wang C, et al. (2017) MicroRNA-145 attenuates TNF-α-driven cartilage matrix degradation in osteoarthritis via direct suppression of MKK4. Cell Death Discov 8: e3140-e3140. https://doi.org/10.1038/cddis.2017.522 ![]() |
[94] |
Chisari E, Yaghmour KM, Khan WS (2020) The effects of TNF-alpha inhibition on cartilage: a systematic review of preclinical studies. Osteoarthr Cartilage 28: 708-718. https://doi.org/10.1016/j.joca.2019.09.008 ![]() |
[95] |
Suurmond J, Dorjée AL, Boon MR, et al. (2011) Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther 13: R150. https://doi.org/10.1186/ar3466 ![]() |
[96] |
Mohamed SA, Neseem NO, Metwally SS, et al. (2018) IL-17 in primary knee osteoarthritis and its relation with severity of the disease. Int J Clin Rheumtol 13: 364-369. https://doi.org/10.4172/1758-4272.1000212 ![]() |
[97] |
Na HS, Park JS, Cho KH, et al. (2020) Interleukin-1-interleukin-17 signaling axis induces cartilage destruction and promotes experimental osteoarthritis. Front Immunol 11: 730. https://doi.org/10.3389/fimmu.2020.00730 ![]() |
[98] |
Liao Y, Ren Y, Luo X, et al. (2022) Interleukin-6 signaling mediates cartilage degradation and pain in posttraumatic osteoarthritis in a sex-specific manner. Sci Signal 15: eabn7082. https://doi.org/10.1126/scisignal.abn7082 ![]() |
[99] |
Wiegertjes R, van de Loo FAJ, Davidson ENB (2020) A roadmap to target interleukin-6 in osteoarthritis. Rheumatology 59: 2681-2694. https://doi.org/10.1093/rheumatology/keaa248 ![]() |
[100] |
Ahmad R, El Mabrouk M, Sylvester J, et al. (2009) Human osteoarthritic chondrocytes are impaired in matrix metalloproteinase-13 inhibition by IFN-γ due to reduced IFN-γ receptor levels. Osteoarthr Cartilage 17: 1049-1055. https://doi.org/10.1016/j.joca.2009.02.008 ![]() |
[101] |
Henrotin YE, Zheng SX, Labasse AH, et al. (2000) Modulation of human chondrocyte metabolism by recombinant human interferon. Osteoarthr Cartilage 8: 474-482. https://doi.org/10.1053/joca.1999.0323 ![]() |
[102] |
Kour S, Garimella MG, Shiroor DA, et al. (2016) IL-3 decreases cartilage degeneration by downregulating matrix metalloproteinases and reduces joint destruction in osteoarthritic mice. J Immunol 196: 5024-5035. https://doi.org/10.4049/jimmunol.1500907 ![]() |
[103] |
van Helvoort EM, van der Heijden E, van Roon JAG, et al. (2022) The role of interleukin-4 and interleukin-10 in osteoarthritic joint disease: A systematic narrative review. Cartilage 13: 194760352210981. https://doi.org/10.1177/19476035221098167 ![]() |
[104] |
Jovanovic D, Pelletier JP, Alaaeddine N, et al. (1998) Effect of IL-13 on cytokines, cytokine receptors and inhibitors on human osteoarthritis synovium and synovial fibroblasts. Osteoarthr Cartilage 6: 40-49. https://doi.org/10.1053/joca.1997.0091 ![]() |
[105] |
Yang CY, Chanalaris A, Bonelli S, et al. (2020) Interleukin 13 (IL-13)-regulated expression of the chondroprotective metalloproteinase ADAM15 is reduced in aging cartilage. Osteoarthr Cartil Open 2: 100128. https://doi.org/10.1016/j.ocarto.2020.100128 ![]() |
[106] | Cook AD, Pobjoy J, Steidl S, et al. (2012) Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. Arthritis Res Ther 14: 1-9. https://doi.org/10.1186/ar4037 |
[107] |
Lee KMC, Prasad V, Achuthan A, et al. (2020) Targeting GM-CSF for collagenase-induced osteoarthritis pain and disease in mice. Osteoarthr Cartilage 28: 486-491. https://doi.org/10.1016/j.joca.2020.01.012 ![]() |
[108] |
Tewari D, Cook AD, Lee MC, et al. (2020) Granulocyte-macrophage colony stimulating factor as an indirect mediator of nociceptor activation and pain. J Neurosci 40: 2189-2199. https://doi.org/10.1523/JNEUROSCI.2268-19.2020 ![]() |
[109] |
Honsawek S, Yuktanandana P, Tanavalee A, et al. (2012) Correlation between plasma and synovial fluid basic fibroblast growth factor with radiographic severity in primary knee osteoarthritis. Int Orthop 36: 981. https://doi.org/10.1007/s00264-011-1435-z ![]() |
[110] |
Takata K, Uchida K, Takano S, et al. (2021) Possible regulation of bFGF expression by mast cells in osteoarthritis patients with obesity: A cross-sectional study. Diabetes Metab Syndr Obes 14: 3291-3297. https://doi.org/10.2147/DMSO.S319537 ![]() |
[111] |
El-Fetiany AE, Kassem EM, El-Barbary AM, et al. (2017) Evaluation of plasma basic fibroblast growth factor (bFGF) in primary knee osteoarthritis patients. Egypt Rheumatol 39: 33-37. https://doi.org/10.1016/j.ejr.2016.03.006 ![]() |
[112] | Im HJ, Sharrocks AD, Lin X, et al. (2009) Basic fibroblast growth factor induces matrix metalloproteinase-13 via eRK MAP kinase-altered phosphorylation and sumoylation of Elk-1 in human adult articular chondrocytes. Open Access Rheumatol Res Rev 1: 151-161. https://doi.org/10.2147/OARRR.S7527 |
[113] |
Li X, Su G, Wang J, et al. (2013) Exogenous bFGF promotes articular cartilage repair via up-regulation of multiple growth factors. Osteoarthr Cartilage 21: 1567-1575. https://doi.org/10.1016/j.joca.2013.06.006 ![]() |
[114] |
Chuma H, Mizuta H, Kudo S, et al. (2004) One day exposure to FGF-2 was sufficient for the regenerative repair of full-thickness defects of articular cartilage in rabbits. Osteoarthr Cartilage 12: 834-842. https://doi.org/10.1016/j.joca.2004.07.003 ![]() |
[115] |
Khan SN, Muhammad H, Scammahorn JJ, et al. (2018) Fibroblast growth factor 2 promotes regeneration of cartilage by attracting mesenchymal stem cells to the site of cartilage injury. Osteoarthr Cartilage 26: S37. https://doi.org/10.1016/j.joca.2018.02.090 ![]() |
[116] |
Vincent TL (2011) Fibroblast growth factor 2: Good or bad guy in the joint?. Arthritis Res Ther 13: 1-2. https://doi.org/10.1186/ar3447 ![]() |
[117] |
Murata M, Yudoh K, Masuko K (2008) The potential role of vascular endothelial growth factor (VEGF) in cartilage: How the angiogenic factor could be involved in the pathogenesis of osteoarthritis?. Osteoarthr Cartilage 16: 279-286. https://doi.org/10.1016/j.joca.2007.09.003 ![]() |
[118] |
Hamilton JL, Nagao M, Levine BR, et al. (2016) Targeting VEGF and its receptors for the treatment of osteoarthritis and associated pain. J Bone Miner Res 31: 911-924. https://doi.org/10.1002/jbmr.2828 ![]() |
[119] |
Wang B, Wu L, Chen J, et al. (2021) Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Signal Transduct Target Ther 6: 1-30. https://doi.org/10.1038/s41392-020-00443-w ![]() |
[120] |
Theoharides TC, Kalogeromitros D (2006) The critical role of mast cells in allergy and inflammation. Ann NY Acad Sci 1088: 78-99. https://doi.org/10.1196/annals.1366.025 ![]() |
[121] |
Miyabe Y, Miyabe C, Luster AD (2017) LTB4 and BLT1 in inflammatory arthritis. Semin Immunol 33: 52-57. https://doi.org/10.1016/j.smim.2017.09.009 ![]() |
[122] |
Wittenberg RH, Willburger RE, Kleemeyer KS, et al. (1993) In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases. Arthritis Rheum 36: 1444-1450. https://doi.org/10.1002/art.1780361017 ![]() |
[123] |
Hansen AK, Indrevik JT, Figenschau Y, et al. (2015) Human articular chondrocytes express functional leukotriene B4 receptors. J Anat 226: 268-277. https://doi.org/10.1111/joa.12275 ![]() |
[124] | He W, Pelletier JP, Martel-Pelletier J, et al. (2002) Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. J Rheumatol 29: 546-553. |
[125] |
Mishima S, Kashiwakura J, Toyoshima S, et al. (2021) Higher PGD2 production by synovial mast cells from rheumatoid arthritis patients compared with osteoarthritis patients via miR-199a-3p/prostaglandin synthetase 2 axis. Sci Rep 11: 1-14. https://doi.org/10.1038/s41598-021-84963-7 ![]() |
[126] | Zayed N, Chabane N, Elmansouri FE, et al. (2010) Prostaglandin D2 enhances interleukin-1β-induced cyclooxygenase-2 expression in osteoarthritic cartilage. J Transl Med 25: 945. https://doi.org/10.1096/fasebj.25.1_supplement.945.15 |
[127] |
Zayed N, Afif H, Chabane N, et al. (2008) Prostaglandin D2 inhibits interleukin-1β-induced matrix metalloproteinase-1 and -13 production by human osteoarthritic chondrocytes. Arthritis Rheum 58: 3530. https://doi.org/10.1002/art.23958 ![]() |
[128] |
Dave M, Amin AR (2013) Yin-Yang regulation of prostaglandins and nitric oxide by PGD2 in human arthritis: Reversal by celecoxib. Immunol Lett 152: 47-54. https://doi.org/10.1016/j.imlet.2013.04.002 ![]() |
[129] |
Fahmi H, Ouhaddi Y (2017) Deletion of the prostaglandin D2 receptor DP1 exacerbates aging-associated and instability-induced osteoarthritis. Osteoarthr Cartilage 25: S153-S154. https://doi.org/10.1016/j.joca.2017.02.255 ![]() |
[130] |
Timur UT, Caron MMJ, Jeuken RM, et al. (2020) Chondroprotective actions of selective COX-2 inhibitors in vivo: A systematic review. Int J Mol Sci 21: 1-15. https://doi.org/10.3390/ijms21186962 ![]() |
[131] |
McCabe PS, Maricar N, Parkes MJ, et al. (2016) The efficacy of intra-articular steroids in hip osteoarthritis: a systematic review. Osteoarthr Cartilage 24: 1509-1517. https://doi.org/10.1016/j.joca.2016.04.018 ![]() |
[132] | Pelletier JP, Lascau-Coman V, Jovanovic D, et al. (1999) Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors. J Rheumatol 26: 2002-2014. |
[133] |
Abramson SB (2008) Osteoarthritis and nitric oxide. Osteoarthr Cartilage 16: S15-S20. https://doi.org/10.1016/S1063-4584(08)60008-4 ![]() |
[134] | Shang X, Wang Y, Cai D, et al. (2022) An inducible nitric oxide synthase dimerization inhibitor prevents the progression of osteoarthritis. Front Pharmacol 13: 2627. https://doi.org/10.3389/fphar.2022.861183 |
[135] |
Han Y, Yang J, Zhao W, et al. (2021) Biomimetic injectable hydrogel microspheres with enhanced lubrication and controllable drug release for the treatment of osteoarthritis. Bioact Mater 6: 3596-3607. https://doi.org/10.1016/j.bioactmat.2021.03.022 ![]() |
[136] |
Huang H, Lou Z, Zheng S, et al. (2022) Intra-articular drug delivery systems for osteoarthritis therapy: shifting from sustained release to enhancing penetration into cartilage. Drug Deliv 29: 767. https://doi.org/10.1080/10717544.2022.2048130 ![]() |